Skip to main
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is a clinical-stage biopharmaceutical company that has a promising pipeline, with two oral amylin agonists in Phase 1 trials and two oral GLP-1 agonists in Phase 3 trials for treating chronic diseases with unmet medical needs. This positions the company for potential growth, but there are risks such as the need for data replication in larger trials and potential competition from established drugs and other therapies in development. As of the company's latest presentation, aleniglipron has shown favorable tolerability rates and a competitive efficacy estimate, but longer-term trials will be needed to validate the data. Further updates from the company's FDA meeting and competitor Phase 3 designs may provide additional insights into the potential of Structure Therapeutics's pipeline.

Bears say

Structure Therapeutics is facing significant challenges to differentiate their molecule in an already crowded market, with key data from Phase 3 trials needing to replicate the lower discontinuation rates and superior weight loss efficacy seen in earlier trials. There may also be limitations to the molecule's tolerability and commercial success, given the potential for competing injectable treatments with more pleiotropic benefits. While the company's oral advantage and cost structure may be appealing, emerging data on nausea and vomiting and the reduction in the price target suggest significant risks to this investment.

GPCR has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 10 analysts, GPCR has a Strong Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.